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Background: While recent research has shown that expression of ZEB-1 in a variety of tumors has a crucial impact
on patient survival, there is little information regarding ZEB-1 expression in hepatocellular carcinoma (HCC). This
study investigated the co-expression of ZEB-1 and E-cadherin in HCC by immunohistochemistry and evaluated its
association with clinical factors, including patient prognosis.
Methods: A total of 108 patients with primary HCC treated by curative hepatectomy were enrolled. ZEB-1
expression was immunohistochemically categorized as positive if at least 1% cancer cells exhibited nuclear staining.
E-cadherin expression was divided into preserved and reduced expression groups and correlations between ZEB-1
and E-cadherin expression and clinical factors were then evaluated.
Results: With respect to ZEB-1 expression, 23 patients were classified into the positive group and 85 into the
negative group. Reduced E-cadherin expression was seen in 44 patients and preserved expression in the remaining
64 patients. ZEB-1 positivity was significantly associated with reduced expression of E-cadherin (p = 0.027). Moreover,
significant associations were found between ZEB-1 expression and venous invasion and TNM stage. ZEB-1 positivity
was associated with poorer prognosis (p = 0.025). Reduced E-cadherin expression was significantly associated with
intrahepatic metastasis and poorer prognosis (p = 0.047). In particular, patients with both ZEB-1 positivity and
reduced E-cadherin expression had a poorer prognosis (p = 0.005). Regardless of E-cadherin status, ZEB-1 was not a
significant prognostic factor by multivariate analysis. There was no statistical difference in overall survival when
E-cadherin expression was reduced in the ZEB-1 positive group (p = 0.24).
Conclusions: Positive ZEB-1 expression and loss of E-cadherin expression are correlated with poor prognosis in
HCC patients and malignancy of ZEB-1 positive tumors involves EMT.
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Hepatocellular carcinoma (HCC) is a major health prob-
lem worldwide, with an estimated incidence ranging be-
tween 500,000 and 1,000,000 new cases annually. It is
the fifth most common cancer in the world, and the
third most common cause of cancer-related death. The
disease is highly lethal because of its aggressive metasta-
sis and an advanced stage at the time of diagnosis [1].* Correspondence: ueno1@m.kufm.kagoshima-u.ac.jp
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distribution, and reproduction in any mediumRecent developments in surgical and medical therapies
have significantly improved the outcome of patients with
both operable and advanced HCC [2,3]. Although there
is recent evidence that these patients benefit from new
molecular targeted therapies, systemic chemotherapy is
not as effective as expected in patients with advanced
HCC [4].
It has recently become clear that epithelial-mesenchymal
transition (EMT) plays an important role in cancer pro-
gression, metastasis and chemoresistance, most likely in-
volving a common molecular mechanism. However, the
involvement of EMT varies greatly among cancer types,
and much remains to be elucidated [5,6]. A hallmark of
EMT is down-regulation of the cell adhesion moleculetral Ltd. This is an open access article distributed under the terms of the
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tablishment of stable adherent junctions, and up-
regulation of mesenchymal molecules including vimentin,
fibronectin and/or N-cadherin. It has been reported that
repression of E-cadherin is associated with dedifferenti-
ation, infiltrative growth and high incidence of lymph
node metastasis in several cancers [7-9]. E-cadherin is
repressed by multiple mechanisms, including gene muta-
tion, promoter hypermethylation, or promoter repression
by transcription repressors during tumor progression. A
variety of transcription factors including the zinc finger
Snail homologues (Snail1, Snail2/Slug, and Snail3) and
several basic helix-loop-helix factors such as Twist, ZEB-
1, and ZEB2, all interact with the E-box element within
the proximal region of the E-cadherin promoter
[5,8,10,11]. ZEB-1, like other EMT-inducing transcription
factors such as Twist, Snail, Slug and SIP, binds DNA
using similar E-box sequence motifs, thereby effecting re-
pression of E-cadherin [12]. Aberrant expression of ZEB-
1 in endometrial cancers, colorectal carcinomas and
prostate cancer has been associated with aggressive dis-
ease, poor differentiation, the development of metastases
and poor clinical prognosis [6,8-10].
In the oncogenic pathway, transforming growth factor-
β (TGF-β) signaling is also critical for EMT induction
[13]. The relationship between TGF-β and cancer pro-
motion has been examined from various viewpoints
[13-16], and recently, it has been reported that TGF-β
stimulates EMT by two mechanisms [14]. The first,
namely canonical signaling, involves a heterocomplex
of activated Smad2/3 and smad4. The second, termed
noncanonical signaling, involves induction of EMT
gene expression by ZEB-1 and other transcription fac-
tors such as Snail, Twist or and Stat3, culminating in
prolonged induction of EMT. We previously observed
elevated expression of Smad4 in 35.5% of patients in
HCC, and that this status was correlated with a poor
prognosis [17].
The aim of this study was to investigate the association
between the expression status of ZEB-1 and E-cadherin
in HCC using immunohistochemistry, and to evaluate
the clinical impact of the expression status of these
proteins.
Methods
Patients and tumor samples
108 patients with primary single nodular HCC (85 men
and 23 women, with a mean age of 65.3 years) were
treated by hepatic partial resection between January
1996 and December 2002. Surgical specimens from
these patients were used in this study. As shown in
Table 1, of these 108 patients, 18 patients were positive
for the hepatitis B surface antigen, 76 were positive for
anti-hepatitis C virus antibodies, 1 was positive for bothviruses and 13 were negative for both viruses. Mean
tumor diameter was 44.3 mm (range 10–150 mm). The
histological grade of each tumor and the tumor staging
were determined by the General Rules for the Clinical
and Pathological Study of Primary Liver Cancer (The
Liver Cancer Study Group of Japan, 2009, 5th edition).
18 tumors (16.7%) showed well-differentiated HCC, 78
(72.2%) tumors were moderately differentiated, and 12
(11.1%) tumors were poorly differentiated. Follow-up
data after surgery were obtained from all patients, with a
median follow-up period of 48.4 months. Before tissue
acquisition, each patient provided written informed con-
sent to participate in the study, which was approved by
the ethics committees of Kagoshima University School
of Medicine.
Antibodies
Goat anti-human polyclonal antibody to ZEB-1 was pur-
chased from SANTA CRUZ BIOTECHNOLOGY, Inc.
(Santa Cruz, CA, USA). Mouse anti-human monoclonal
antibody to E-cadherin was purchased from DAKO
JAPAN (Tokyo, Japan).
Immunohistochemistry
Avidin-biotinylated peroxidase complex (ABC) immuno-
histochemistry was performed as follows. 4-mm thick
sections were cut from paraffin blocks of HCC. After
deparaffinization and rehydration, heat-induced antigen
retrieval by autoclave pretreatment (120°C for 10 min)
in citrate buffer solution (pH 6.0) was performed. En-
dogenous peroxidase activity was blocked by immersing
the slides in absolute methanol solution containing 3%
hydrogen peroxide for 10 min. Endogenous biotin acti-
vity was blocked using an avidin/biotin blocking kit
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were incubated in avidin solution for 15 minutes
followed a by brief rinse in PBS, after which sections
were incubated in biotin solution for 15 minutes (all at
room temperature). Sections were then treated with 1%
bovine serum albumin for 30 min to block nonspecific
reactions, after which they were incubated with ZEB-1
antibody (1:100 dilution) or E-cadherin antibody (1:100
dilution) for one hour at room temperature. Following
incubation, specimens were visualized with an ABC de-
tection kit (Vector laboratory, Burlingame, CA) and a di-
aminobenzidine (DAB) substrate system, according to
the instructions provided by the manufacturer. Slides
were counterstained with hematoxylin before mounting.
All reactions were performed using appropriate positive
and negative controls, and no significant staining was
observed in the negative control sections.
Evaluation of immunohistochemistry
In order to evaluate the results by immunohistochemical
staining, ten fields of each specimen were selected. The
expression in 1,000 tumor cells (100 cells/field) was eval-
uated with high-power (×400) microscopy. Two investi-
gators (M.H. and S.U.) assessed the slides without
knowledge of the clinicopathological features and were
blinded to each other’s evaluation. They were in agree-
ment on all the slides examined.
Statistical analysis
Statistical analysis of group differences was performed
using the χ2 test or Student’s t-test. The Kaplan-Meier
method and subsequent evaluation by log-rank test were
used for overall survival analysis. The prognostic factors
were examined by univariate and multivariate analyses
(proportional hazards regression model). A P-value
of less than 0.05 was considered to be statistically
significant.
Results
Expression of ZEB-1 and E-cadherin in HCC
ZEB-1 was detected in the cellular nuclei of HCC cells
(Figure 1a). All noncancerous liver cells were ZEB-1
negative (Figure 1c). ZEB-1 expression was classified
into four groups: absent (n = 85; Figure 1e), 1 ~ 5% of all
cancer cells (n = 12), 6 ~ 10% (n = 7) and >10% (n = 4).
Since the frequency of ZEB-1 expression was low, ZEB-1
expression was categorized as positive if at least 1% of
cancer cells exhibited nuclear staining (n = 23; 21.3%) or
as negative if very few or no cancer cells were stained
(n = 85; 78.7%).
E-cadherin was detected in the cellular membranes of
HCC and in the normal glands of the liver (Figure 1d, f ).
E-cadherin expression was compared between malignant
cells and noncancerous liver cells located away from thetumor. Tumor cells with a staining intensity equal to or
greater than that of noncancerous liver cells were
considered to be preserved expression (n = 64, 59.3%;
Figure 1f )), whereas those with a weaker staining inten-
sity than noncancerous liver cells or with no expression
at all, were considered to be reduced expression (n = 44,
40.7%; Figure 1b).
Correlation between ZEB-1 and E-cadherin expression
and clinicopathological factors
Table 2 shows the correlation between immunohisto-
chemical expression and clinicopathological factors.
Positive expression of ZEB-1 in 23 HCCs (21.3%) was
significantly associated with vascular invasion (p = 0.016)
and advanced tumor TNM stage (p = 0.023). Further-
more, there was a trend towards an increased frequency
of intrahepatic metastasis in the ZEB-1 positive group
(p = 0.078). Reduced E-cadherin expression in 44 HCCs
(40.7%) was significantly associated with intrahepatic
metastasis (p < 0.001) and advanced tumor stage
(p = 0.05).
Finally, reduced E-cadherin expression was signifi-
cantly associated with positive ZEB-1 expression
(p = 0.027).
Prognostic impact of ZEB-1 and E-cadherin expression
Figure 2a & b shows overall survival curves after surgery
according to ZEB-1 and E-cadherin expression (Fig-
ure 2a, b). The 5-year survival rates of patients with
positive and negative expression of ZEB-1 were 38.1 and
63.4%, respectively (p = 0.025). Similarly, the 5-year sur-
vival rate was significantly better in the E-cadherin pre-
served group than in the reduced E-cadherin group (5-
year 66.0 vs. 45.5%, p = 0.048).
Overall survival was evaluated according to the various
combinations of the expression patterns of ZEB-1 and
E-cadherin. When comparing between patients with
ZEB-1 positive and reduced E-cadherin expression and
patients with other expression pattern combinations
(Figure 2c), the former group showed a significantly
poorer prognosis (5-year 29.5 vs. 62.2%, p = 0.005).
There was no statistical difference in overall survival
when E-cadherin expression was reduced in the ZEB-1
positive group (p = 0.24) (Figure 2d).
Univariate and multivariate analyses
Factors relating to the patients’ prognosis were evaluated
by univariate and multivariate analyses (Table 3). Univar-
iate analysis showed that intrahepatic metastasis (p =
0.0007), vascular invasion (p = 0.047) and ZEB-1 expres-
sion (p = 0.037) were significantly related to postopera-
tive survival. There was a strong trend towards
association of reduced E-cadherin expression with poor
prognosis (p = 0.053). In the multivariate analysis, only
Figure 1 Immunohistochemical analysis of ZEB-1 and E-cadherin expression. ZEB-1 antibody was purchased from SANTA CRUZ BIOTECH-
NOLOGY, Inc. and E-cadherin antibody was purchased from DAKO JAPAN. Images from representative cases are shown: case 1 (a - d) and case 2
(e. f). Case 1 was classified as >10% ZEB-1 positive. a. Positive expression of ZEB-1 in cellular nuclei in HCC. b. Reduced expression of E-cadherin
in HCC cells. c. ZEB-1 expression is undetectable in noncancerous liver cells. d. E-cadherin expression was observed in the cell membrane in
noncancerous liver cells. Case 2 was classified as ZEB-1 negative. e. ZEB-1 was not detected in the cell nuclei in HCC cells. f. E-cadherin expression
was preserved in the cell membrane in HCC cells.
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prognostic factor.
Discussion
ZEB-1 (also known as dEF1, Nil-2-a, Tcf8, Bzp, Areb6,
Meb1, Zfhx1a and Zfhep) has been identified as a nu-
clear factor that specifically binds to and represses the
avian lens-specific d1-crystallin enhancer [18]. ZEB-1 is
a DNA binding transcriptional repressor that interacts
in a ligand-dependent fashion with receptor-activated
Smad transcription factors involved in mediating TGF-β
signaling [19]. Recent research has shown that expres-
sion of ZEB-1 has a crucial impact on patient survival
[20]. Positive expression of ZEB-1 in endometrialcancers, colorectal carcinomas, and prostate cancer has
been associated with aggressive disease, poor differenti-
ation, development of metastases, and poor clinical
prognosis [21-24]. In contrast, there is little information
regarding the clinical implications of ZEB-1 expression
in HCC, nor the relationship between ZEB-1 and
E-cadherin expression in HCC.
In this study, we immunohistochemically investigated
ZEB-1 expression in HCC and evaluated its association
with clinical factors, including patient prognosis. For the
purposes of this study, ZEB-1 positive expression was
defined as >1% ZEB-1 positive HCC cells, although it
should be noted that this is not an established method.
A similar ZEB-1 positive percentage (14/110, 12%) in














Male 85 18 67 0.996 47 38 0.107
Female 23 5 18 17 6
Tumor size (mm)
≧4.5 cm 33 10 27 0.227 21 16 0.702
<4.5 cm 75 13 58 43 28
Vascular invasion
Present 38 13 25 0.016 21 17 0.533
Absent 70 10 60 43 27
Infiltration into capsule (Fc-inf)
Present 84 18 66 0.95 51 33 0.565
Absent 24 5 19 13 11
Intrahepatic metastasis
Present 27 9 18 0.078 13 33 <0.001
Absent 81 14 67 51 11
Gross classification*
Localized 69 13 56 0.095 43 26 0.389
Invasive 29 10 19 21 18
Differentiation*
Well 18 3 15 0.5 9 9 0.717
Moderate 76 15 61 46 30
Poor 12 4 8 7 5
PIVKA II level (mAU/ml) (n = 91)
Normal (≦40 ) 23 5 18 0.906 16 7 0.36
High (>40 ) 68 14 54 40 28
AFP level (ng/ml) (n = 95)
Normal (≦20 ) 48 10 38 0.837 29 19 0.732
High (>20 ) 47 9 38 30 17
Pathological TMN Stage*
I + II + III 88 15 73 0.023 56 32 0.05
IV 20 8 12 8 12
Immunohistochemical staining
ZEB-1 0.027
Positive 23 9 14
negative 80 55 30
*The histological grade of each tumor and the tumor staging were determined by the General Rules for the Clinical and Pathological Study of Primary Liver
Cancer (The Liver Cancer Study Group of Japan, 2009, 5th edition).
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chemical analysis [25]. We showed that positive expres-
sion of ZEB-1 was significantly associated with vascular
invasion (p = 0.016), tumor TNM stage (p = 0.024), and
prognosis (p = 0.025). Using western blot, Zhou et al.
showed that elevated expression of ZEB-1 occurred in65.4% (72/110) of HCC tissues and was a significant
prognostic factor for poor overall and disease-free sur-
vival rates [26]. A caveat of Western blot is that it may
not completely exclude the influence of differences in
expression in different regions of the tumor, nor the
contribution of contaminating fibroblasts. In order to
Figure 2 Overall survival curves for each immunohistochemical staining group. a. The 5-year survival rate was significantly lower in the
ZEB-1 positive group than in the ZEB-1 negative group (5-year 38.1 vs. 63.4%, p = 0.025). b. The 5-year survival rate was significantly higher in the
preserved E-cadherin group than in the reduced E-cadherin group (5-year 66.0 vs. 45.5%, p = 0.048). c. When comparing between patients with
ZEB-1 positive/ E-cadherin reduced and patients with other expression pattern combinations, ZEB-1(+)/E-cadherin(−) group showed a significantly
poorer prognosis (5-year 29.5 vs. 62.2%, p = 0.005). d. There was no statistical difference in overall survival when E-cadherin expression was
reduced in the ZEB-1 positive group (p = 0.24).
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expression in HCC cells should be studied in isolation.
Accordingly, in the present study we examined ZEB-1
expression using immunohistochemical analysis. In this
report, while the frequency of ZEB1 expression in the
nuclei of HCC cells was lower than that in previous re-
ports [26], patient prognosis was significantly poorer
when ZEB-1 positive cells were present in HCC tissues.
Moreover, increased ZEB-1 expression cells was associ-
ated with markedly worse prognosis (data not shown).Table 3 Univariate and Multivariate analysis of overall surviv
Univariate
Variables HR 95%CI
Intrahepatic metastasis 1.80 1.30-2.47
Vascular invasion 0.72 1.00-1.88
Positive ZEB1 1.45 1.02-2.00
Reducing E-cadherin 1.36 1.00-1.86We suggest that immunohistochemical evaluation of
ZEB-1 expression in tumor nuclei may have clinical
prognostic impact.
Reduced E-cadherin expression has been observed in
HCC, in particular in poorly-differentiated cancers
[27,28]. We also showed that reduced expression of E-
cadherin was significantly associated with increased
intrahepatic metastasis (p < 0.001) and poorer prognosis
(p = 0.048). When we analyzed the relationship between
ZEB-1 and E-cadherin expression, the combination ofal
Multivariate
p-value HR 96%CI p-value
0.0007 1.67 1.14-2.41 0.0086
0.047 1.08 0.74-1.55 0.696
0.037 1.20 0.83-1.71 0.320
0.053 1.31 0.95-1.81 0.101
Hashiguchi et al. BMC Cancer 2013, 13:572 Page 7 of 8
http://www.biomedcentral.com/1471-2407/13/572positive ZEB-1 expression and reduced E-cadherin ex-
pression was associated with the worst prognosis among
the various combinations of ZEB-1 and E-cadherin
expression. Again using western blot, Zhou et al. also
observed a significant correlation between lower E-
cadherin protein expression and elevated ZEB-1 expres-
sion in HCC specimens [26]. High expression of ZEB-1
may further enhance its inhibition of the expression of
the E-cadherin gene, causing a decrease in E-cadherin
levels and an increase in migration and invasiveness in
cancer cells [21-24,29,30]. Acquisition of an invasive
phenotype through EMT, which enables cancer cells to
break away from the primary tumor and invade sur-
rounding tissues, may strongly promote the spread of
cancer cells into the portal venous circulation.
During the EMT process, epithelial cancer cells ac-
quire fibroblast-like properties and malignant potential
through both canonical and non-canonical TGF-β sig-
naling pathways [13,14]. Activation of canonical Smad2/
3 signaling results in nuclear translocation of these fac-
tors with Smad4 and subsequent regulation of gene ex-
pression through their numerous interactions with
additional transcriptional activators and repressors. We
have previously shown that strong expression of Smad4
occurs in 35.5% of patients in HCC, and is associated
with a poor prognosis (p = 0.04) [17]. In this study how-
ever, we found that a combination of ZEB1 and E-
cadherin expression was a more powerful statistical tool
than Smad4 in predicting clinical outcome. Alternatively,
activation of factors in noncanonical TGF-β signaling,
such as MAP kinases, small GTPases, PI3K/AKT, and
NF-κB, also couples TGF-β to regulation of EMT ex-
pression programs. Finally, activation of transcription
factors belonging to the Snail family (e.g., Snail, Twist,
or ZEB-1), or of Stat3, induces genes associated with
EMT, which ultimately promotes progression of EMT.
In this study, we correlated positive expression of ZEB-1
and reduced expression of E-cadherin with poorer
prognosis in HCC. We speculate that EMT is active in
ZEB-1 positive tumors, and that both canonical and
noncanonical signaling systems are influential in HCC.Conclusions
In conclusion, it is likely that positive ZEB-1 expression
and reduced E-cadherin expression are correlated with
the progression of HCC through their influence on the
progression of EMT. Accordingly, inhibition of the ex-
pression or function of EMT-inducing transcription fac-
tors in malignant carcinoma is anticipated to lead to
new therapeutic strategies.Competing interests
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